PATIENTS: Soft tissue sarcomas are uncommon malignancies with few therapeutic options for recurrent or metastatic disease. Dolastatin-10 (Dol-10) is a pentapeptide anti-microtubule agent that binds to tubulin sites distinct from vinca alkaloids. Based on the novel mechanism of action, limited activity of other anti-microtubular agents, and anti-neoplastic activity in pre-clinical screening of Dol-10, this multi-institutional phase II study was conducted to determine the objective response rate of Dol-10 in recurrent or metastatic soft tissue sarcomas that had not been treated with chemotherapy outside of the adjuvant setting. METHODS: Dol-10 was given intravenously at a dose of 400 mug/m(2) and repeated every 21 days. Toxicities were assessed using the Common Toxicity Criteria (version 2.0). Radiographic studies and tumor measurements were repeated every two cycles to assess response [Miller AB, et al. Cancer 1981; 47(1): 207]. RESULTS: Dol-10 was associated with hematological toxicity and with some vascular toxicities. There was no significant gastrointestinal, hepatic or renal toxicity. There was one death on study due to respiratory failure. There were no objective responses in 12 patients treated with Dol-10. DISCUSSION: Based on this phase II trial, further study of Dol-10 on this schedule is not recommended in advanced or metastatic soft tissue sarcomas.
PATIENTS: Soft tissue sarcomas are uncommon malignancies with few therapeutic options for recurrent or metastatic disease. Dolastatin-10 (Dol-10) is a pentapeptide anti-microtubule agent that binds to tubulin sites distinct from vinca alkaloids. Based on the novel mechanism of action, limited activity of other anti-microtubular agents, and anti-neoplastic activity in pre-clinical screening of Dol-10, this multi-institutional phase II study was conducted to determine the objective response rate of Dol-10 in recurrent or metastatic soft tissue sarcomas that had not been treated with chemotherapy outside of the adjuvant setting. METHODS:Dol-10 was given intravenously at a dose of 400 mug/m(2) and repeated every 21 days. Toxicities were assessed using the Common Toxicity Criteria (version 2.0). Radiographic studies and tumor measurements were repeated every two cycles to assess response [Miller AB, et al. Cancer 1981; 47(1): 207]. RESULTS:Dol-10 was associated with hematological toxicity and with some vascular toxicities. There was no significant gastrointestinal, hepatic or renal toxicity. There was one death on study due to respiratory failure. There were no objective responses in 12 patients treated with Dol-10. DISCUSSION: Based on this phase II trial, further study of Dol-10 on this schedule is not recommended in advanced or metastatic soft tissue sarcomas.
Authors: C Bokemeyer; A Franzke; J T Hartmann; C Schöber; L Arseniev; B Metzner; H Link; L Kanz; H J Schmoll Journal: Cancer Date: 1997-10-01 Impact factor: 6.860
Authors: E Galanis; E M Hersh; A T Stopeck; R Gonzalez; P Burch; C Spier; E T Akporiaye; J J Rinehart; J Edmonson; R E Sobol; C Forscher; V K Sondak; B D Lewis; E C Unger; M O'Driscoll; L Selk; J Rubin Journal: J Clin Oncol Date: 1999-10 Impact factor: 44.544
Authors: A Le Cesne; G Vassal; F Farace; M Spielmann; T Le Chevalier; E Angevin; D Valteau-Couanet; K Fizazi; I Cojean; A Llombard; T Tursz; B Escudier Journal: J Immunother Date: 1999-05 Impact factor: 4.456
Authors: B E Plaat; H Hollema; W M Molenaar; G H Torn Broers; J Pijpe; M F Mastik; H J Hoekstra; E van den Berg; R J Scheper; W T van der Graaf Journal: J Clin Oncol Date: 2000-09-15 Impact factor: 44.544
Authors: H C Pitot; E A McElroy; J M Reid; A J Windebank; J A Sloan; C Erlichman; P G Bagniewski; D L Walker; J Rubin; R M Goldberg; A A Adjei; M M Ames Journal: Clin Cancer Res Date: 1999-03 Impact factor: 12.531
Authors: J-Y Blay; M van Glabbeke; J Verweij; A T van Oosterom; A Le Cesne; J W Oosterhuis; I Judson; O S Nielsen Journal: Eur J Cancer Date: 2003-01 Impact factor: 9.162